Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase IIIb study of Asciminib in patients with CML

An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation

Disease Types: Leukemia

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation

For more information:

https://clinicaltrials.gov/ct2/show/NCT04666259?cond=An+open+label%2C+multi-center+Phase+IIIb+study+of+asciminib+%28ABL001%29+monotherapy+in+previously+treated+patients+with+chronic+myeloid+leukemia+in+chronic+phase+%28CML-CP%29+with+and+without+T315I+mutation&draw=2&rank=1